157 related articles for article (PubMed ID: 36947408)
1. Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance.
Meijboom RW; Barbier L; Druedahl LC; Sarnola K; Tolonen HM; Gardarsdottir H; Egberts TCG; Giezen TJ
Expert Opin Biol Ther; 2023; 23(8):801-817. PubMed ID: 36947408
[TBL] [Abstract][Full Text] [Related]
2. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
Park SK; Moon W; Kim ES; Park SH; Park DI
Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey.
Maltz RM; McClinchie MG; Boyle BM; McNicol M; Morris GA; Crawford EC; Moses J; Kim SC
J Pediatr Gastroenterol Nutr; 2023 May; 76(5):616-621. PubMed ID: 36827968
[TBL] [Abstract][Full Text] [Related]
4. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
[TBL] [Abstract][Full Text] [Related]
5. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
6. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
[TBL] [Abstract][Full Text] [Related]
7. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
Bokemeyer B; Dignaß A; Schreiber S
Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
[TBL] [Abstract][Full Text] [Related]
8. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
[TBL] [Abstract][Full Text] [Related]
9. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
[TBL] [Abstract][Full Text] [Related]
10. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar infliximab use in paediatric IBD.
Richmond L; Curtis L; Garrick V; Rogers P; Wilson M; Tayler R; Henderson P; Hansen R; Wilson DC; Russell RK
Arch Dis Child; 2018 Jan; 103(1):89-91. PubMed ID: 28988215
[TBL] [Abstract][Full Text] [Related]
13. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
14. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
[TBL] [Abstract][Full Text] [Related]
16. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
17. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
[TBL] [Abstract][Full Text] [Related]
18. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
